| CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer EM Bange, NA Han, P Wileyto, JY Kim, S Gouma, J Robinson, ... Nature medicine 27 (7), 1280-1289, 2021 | 420 | 2021 |
| PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's … AJ Moskowitz, H Schöder, J Yahalom, SJ McCall, SY Fox, J Gerecitano, ... The lancet oncology 16 (3), 284-292, 2015 | 283 | 2015 |
| Imaging for staging and response assessment in lymphoma SA Johnson, A Kumar, MJ Matasar, H Schöder, J Rademaker Radiology 276 (2), 323-338, 2015 | 180 | 2015 |
| Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma AJ Moskowitz, H Schöder, S Gavane, KL Thoren, M Fleisher, J Yahalom, ... Blood, The Journal of the American Society of Hematology 130 (20), 2196-2203, 2017 | 132 | 2017 |
| Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JD Soumerai, ... Blood cancer journal 10 (7), 74, 2020 | 127 | 2020 |
| Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, ... Journal of clinical oncology 39 (28), 3109, 2021 | 125 | 2021 |
| Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era: findings from a large national database A Kumar, A Vanderplas, AS LaCasce, MA Rodriguez, AL Crosby, ... Cancer 118 (11), 2944-2951, 2012 | 105 | 2012 |
| Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse A Kumar, F Sha, A Toure, A Dogan, A Ni, CL Batlevi, MLM Palomba, ... Blood cancer journal 9 (6), 50, 2019 | 95 | 2019 |
| Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin, MA Perales, M Scordo, ... Blood advances 4 (19), 4669-4678, 2020 | 87 | 2020 |
| Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma A Kumar, C Casulo, J Yahalom, H Schöder, PM Barr, P Caron, A Chiu, ... Blood, The Journal of the American Society of Hematology 128 (11), 1458-1464, 2016 | 77 | 2016 |
| Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms NE Lewis, K Petrova-Drus, S Huet, ZD Epstein-Peterson, Q Gao, ... Blood advances 4 (10), 2261-2271, 2020 | 72 | 2020 |
| Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small … JD Soumerai, AR Mato, A Dogan, VE Seshan, E Joffe, K Flaherty, J Carter, ... The Lancet Haematology 8 (12), e879-e890, 2021 | 71 | 2021 |
| A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL CS Sauter, MJ Matasar, H Schoder, SM Devlin, P Drullinsky, J Gerecitano, ... Blood, The Journal of the American Society of Hematology 131 (16), 1805-1808, 2018 | 69 | 2018 |
| Prevalence, prognosis, and implications of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults: Cardiovascular Health Study A Kumar, RJ Prineas, AM Arnold, BM Psaty, CD Furberg, J Robbins, ... Circulation 118 (25), 2790-2796, 2008 | 68 | 2008 |
| Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma ME Mayerhoefer, CC Riedl, A Kumar, P Gibbs, M Weber, I Tal, J Schilksy, ... European Journal of Nuclear Medicine and Molecular Imaging 46, 2760-2769, 2019 | 62 | 2019 |
| Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes A Kumar, IA Burger, Z Zhang, EN Drill, JC Migliacci, A Ng, A LaCasce, ... Haematologica 101 (10), 1237, 2016 | 57 | 2016 |
| Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma S Borchmann, E Joffe, CH Moskowitz, AD Zelenetz, A Noy, CS Portlock, ... Blood, The Journal of the American Society of Hematology 133 (20), 2121-2129, 2019 | 54 | 2019 |
| CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer EM Bange, NA Han, P Wileyto, JY Kim, S Gouma, J Robinson, ... Research square, 2021 | 48 | 2021 |
| Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era S Bobillo, E Joffe, JA Lavery, D Sermer, P Ghione, A Noy, PC Caron, ... Blood, The Journal of the American Society of Hematology 137 (1), 39-48, 2021 | 47 | 2021 |
| Recurrent somatic JAK3 mutations in NK-cell enteropathy W Xiao, GK Gupta, J Yao, YJ Jang, L Xi, J Baik, A Sigler, A Kumar, ... Blood, The Journal of the American Society of Hematology 134 (12), 986-991, 2019 | 46 | 2019 |
